Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
According to our market capitalization data, Eli Lilly (LLY) reached a market cap of $678.07 billion, securing the top spot among global Pharmaceuticals companies. Novo Nordisk A/S (NOVO-B.CO) and Johnson & Johnson (JNJ) follow closely behind. The data was last updated on January 22, 2025.
| Rank | Name | Market Cap | Price | MCap(30D) | MCap(1Y) | Country |
|---|---|---|---|---|---|---|
|
401
|
 Benitec Biopharma
BNTC
|
$0.25 B | $10.69 |
-11.1%
|
256.2%
|
United States
|
|
402
|
 Heron Therapeutics
HRTX
|
$0.25 B | $1.63 |
3.2%
|
-25.9%
|
United States
|
|
403
|
 Verastem Oncology
VSTM
|
$0.25 B | $5.52 |
36.7%
|
-50.4%
|
United States
|
|
404
|
 Perspective Therapeutics
CATX
|
$0.24 B | $3.60 |
5.5%
|
-27.0%
|
United States
|
|
405
|
 Foghorn Therapeutics
FHTX
|
$0.24 B | $4.37 |
-14.1%
|
32.6%
|
United States
|
|
406
|
 Sangamo Therapeutics
SGMO
|
$0.24 B | $1.15 |
-56.4%
|
142.2%
|
United States
|
|
407
|
 Lifecore Biomedical
LFCR
|
$0.24 B | $6.43 |
-14.7%
|
-0.77%
|
United States
|
|
408
|
 Neurogene
NGNE
|
$0.24 B | $15.95 |
-26.6%
|
-45.3%
|
United States
|
|
409
|
 ProQR
PRQR
|
$0.24 B | $2.23 |
-16.5%
|
10.9%
|
Netherlands
|
|
410
|
 Tevogen Bio
TVGN
|
$0.24 B | $1.35 |
19.6%
|
-88.7%
|
United States
|
|
411
|
 Avacta Group
AVCT.L
|
$0.23 B | $59.09 |
2.2%
|
-51.3%
|
United Kingdom
|
|
412
|
 Amarin Corporation
AMRN
|
$0.22 B | $0.55 |
23.9%
|
-52.9%
|
Ireland
|
|
413
|
 Abeona Therapeutics
ABEO
|
$0.22 B | $5.14 |
-8.1%
|
7.2%
|
United States
|
|
414
|
 Larimar Therapeutics
LRMR
|
$0.22 B | $3.46 |
-11.6%
|
-25.8%
|
United States
|
|
415
|
 Fulcrum Therapeutics
FULC
|
$0.22 B | $4.09 |
-13.0%
|
-41.1%
|
United States
|
|
416
|
 Ocugen
OCGN
|
$0.22 B | $0.76 |
-1.1%
|
33.0%
|
United States
|
|
417
|
 Hester Biosciences
HESTERBIO.NS
|
$0.21 B | $25.14 |
-7.2%
|
47.8%
|
India
|
|
418
|
 4D Molecular Therapeutics
FDMT
|
$0.21 B | $4.61 |
-21.2%
|
-75.2%
|
United States
|
|
419
|
 Inventiva
IVA
|
$0.21 B | $2.17 |
-1.4%
|
-43.6%
|
France
|
|
420
|
 Sensorion SA
ALSEN.PA
|
$0.21 B | $0.70 |
7.1%
|
28.1%
|
France
|
|
421
|
 Monopar Therapeutics
MNPR
|
$0.21 B | $33.67 |
29.4%
|
1507.9%
|
United States
|
|
422
|
 Gossamer Bio
GOSS
|
$0.20 B | $0.90 |
14.0%
|
13.2%
|
United States
|
|
423
|
 ACELYRIN
SLRN
|
$0.20 B | $2.02 |
-37.2%
|
-71.0%
|
United States
|
|
424
|
 Bliss GVS Pharma
BLISSGVS.NS
|
$0.20 B | $1.92 |
1.2%
|
42.8%
|
India
|
|
425
|
 Cybin
CYBN
|
$0.20 B | $10.01 |
0.94%
|
-33.6%
|
Canada
|
|
426
|
 MediWound
MDWD
|
$0.20 B | $18.41 |
3.0%
|
41.1%
|
Israel
|
|
427
|
 Inhibrx
INBX
|
$0.20 B | $13.60 |
-6.9%
|
-21.6%
|
United States
|
|
428
|
 Molecular Partners
MOLN
|
$0.20 B | $5.33 |
-0.19%
|
15.2%
|
Switzerland
|
|
429
|
 Orchestra BioMed
OBIO
|
$0.20 B | $5.16 |
12.3%
|
-43.9%
|
United States
|
|
430
|
 MacroGenics
MGNX
|
$0.19 B | $3.08 |
-8.0%
|
-75.0%
|
United States
|
|
431
|
 Procaps Group
PROC
|
$0.19 B | $1.69 |
-34.7%
|
-61.4%
|
Luxembourg
|
|
432
|
 Vaxart
VXRT
|
$0.19 B | $0.82 |
21.3%
|
-7.5%
|
United States
|
|
433
|
 Genfit
GNFT
|
$0.18 B | $3.60 |
-1.9%
|
-7.5%
|
France
|
|
434
|
 Oriola Oyj
OKDAV.HE
|
$0.18 B | $1.00 |
5.5%
|
-13.1%
|
Finland
|
|
435
|
 Nkarta
NKTX
|
$0.18 B | $2.48 |
5.1%
|
-68.8%
|
United States
|
|
436
|
 Protalix BioTherapeutics
PLX
|
$0.17 B | $2.37 |
30.9%
|
50.3%
|
Israel
|
|
437
|
 Acrivon Therapeutics
ACRV
|
$0.17 B | $5.60 |
-7.2%
|
36.0%
|
United States
|
|
438
|
 Alector
ALEC
|
$0.17 B | $1.78 |
-7.6%
|
-72.1%
|
United States
|
|
439
|
 Idorsia
IDIA.SW
|
$0.17 B | $0.91 |
1.3%
|
-36.8%
|
Switzerland
|
|
440
|
 INmune Bio
INMB
|
$0.17 B | $7.67 |
43.7%
|
-41.7%
|
United States
|
|
441
|
 Nektar Therapeutics
NKTR
|
$0.17 B | $0.92 |
-2.2%
|
74.5%
|
United States
|
|
442
|
 Lyell Immunopharma
LYEL
|
$0.17 B | $0.58 |
-6.0%
|
-72.6%
|
United States
|
|
443
|
 Greenwich LifeSciences
GLSI
|
$0.17 B | $12.71 |
5.4%
|
48.3%
|
United States
|
|
444
|
 AFT Pharmaceuticals Ltd
AFT.NZ
|
$0.16 B | $1.57 |
-4.5%
|
-22.4%
|
New Zealand
|
|
445
|
 ADC Therapeutics
ADCT
|
$0.16 B | $1.70 |
-13.3%
|
-10.7%
|
Switzerland
|
|
446
|
 Bastide Le Confort Médical SA
BLC.PA
|
$0.16 B | $22.12 |
-12.2%
|
-5.5%
|
France
|
|
447
|
 Vor Biopharma
VOR
|
$0.16 B | $1.31 |
52.0%
|
-43.2%
|
United States
|
|
448
|
 Protara Therapeutics
TARA
|
$0.16 B | $4.69 |
-12.0%
|
132.1%
|
United States
|
|
449
|
 Sutro Biopharma
STRO
|
$0.16 B | $1.97 |
4.1%
|
-58.2%
|
United States
|
|
450
|
 Lexeo Therapeutics
LXEO
|
$0.16 B | $4.90 |
-20.2%
|
-70.4%
|
United States
|
|
451
|
 Zentalis Pharmaceuticals
ZNTL
|
$0.16 B | $2.26 |
-30.4%
|
-83.6%
|
United States
|
|
452
|
 Cellectis S.A.
ALCLS.PA
|
$0.16 B | $1.59 |
4.8%
|
-41.2%
|
France
|
|
453
|
 scPharmaceuticals
SCPH
|
$0.16 B | $3.21 |
-3.0%
|
-40.0%
|
United States
|
|
454
|
 Cellectis
CLLS
|
$0.16 B | $1.53 |
18.6%
|
-36.0%
|
France
|
|
455
|
 Seres Therapeutics
MCRB
|
$0.16 B | $0.91 |
-20.1%
|
-36.6%
|
United States
|
|
456
|
 Ventyx Biosciences
VTYX
|
$0.15 B | $2.16 |
-11.0%
|
0.00%
|
United States
|
|
457
|
 Fate Therapeutics
FATE
|
$0.15 B | $1.34 |
-23.5%
|
-73.7%
|
United States
|
|
458
|
 Veru
VERU
|
$0.15 B | $1.04 |
55.6%
|
139.0%
|
United States
|
|
459
|
 Nanobiotix
NBTX
|
$0.15 B | $3.21 |
-3.7%
|
-62.6%
|
France
|
|
460
|
 Coherus BioSciences
CHRS
|
$0.15 B | $1.31 |
-5.4%
|
-42.1%
|
United States
|
|
461
|
 Innate Pharma
IPHA
|
$0.15 B | $1.77 |
-14.1%
|
-32.4%
|
France
|
|
462
|
 Lineage Cell Therapeutics
LCTX
|
$0.15 B | $0.68 |
9.3%
|
-43.3%
|
United States
|
|
463
|
 Telomir Pharmaceuticals
TELO
|
$0.15 B | $4.98 |
-5.6%
|
-6.2%
|
United States
|
|
464
|
 InflaRx
IFRX
|
$0.15 B | $2.50 |
-1.6%
|
43.6%
|
Germany
|
|
465
|
 Adaptimmune Therapeutics
ADAP
|
$0.15 B | $0.57 |
7.1%
|
-18.4%
|
United Kingdom
|
|
466
|
 Inotiv
NOTV
|
$0.15 B | $4.41 |
-5.7%
|
23.1%
|
United States
|
|
467
|
 Puma Biotechnology
PBYI
|
$0.14 B | $2.95 |
-1.7%
|
-40.7%
|
United States
|
|
468
|
 TScan Therapeutics
TCRX
|
$0.14 B | $2.52 |
-17.5%
|
-52.4%
|
United States
|
|
469
|
 Kyverna Therapeutics
KYTX
|
$0.14 B | $3.29 |
-15.9%
|
-88.9%
|
United States
|
|
470
|
 Corbus Pharmaceuticals
CRBP
|
$0.14 B | $11.35 |
-9.5%
|
63.3%
|
United States
|
|
471
|
 Sagimet Biosciences
SGMT
|
$0.14 B | $4.25 |
-11.1%
|
-74.9%
|
United States
|
|
472
|
 Laboratorios Richmond S.A.C.I.F.
RICH.BA
|
$0.13 B | $1.65 |
0.00%
|
0.00%
|
Argentina
|
|
473
|
 2seventy bio
TSVT
|
$0.13 B | $2.52 |
-13.9%
|
-15.8%
|
United States
|
|
474
|
 Instil Bio
TIL
|
$0.13 B | $19.72 |
-4.2%
|
96.3%
|
United States
|
|
475
|
 Renovaro Biosciences
RENB
|
$0.13 B | $0.80 |
-31.4%
|
-84.8%
|
United States
|
|
476
|
 Solid Biosciences
SLDB
|
$0.12 B | $3.12 |
-21.8%
|
-58.1%
|
United States
|
|
477
|
 Cabaletta Bio
CABA
|
$0.12 B | $2.54 |
17.1%
|
-86.4%
|
United States
|
|
478
|
 Zomedica Pharmaceuticals
ZOM
|
$0.12 B | $0.13 |
8.3%
|
-2.3%
|
United States
|
|
479
|
 Alto Neuroscience
ANRO
|
$0.12 B | $4.52 |
13.4%
|
-77.6%
|
United States
|
|
480
|
 Atossa Therapeutics
ATOS
|
$0.12 B | $0.96 |
-19.4%
|
1.2%
|
United States
|
|
481
|
 Nuvectis Pharma
NVCT
|
$0.12 B | $6.10 |
18.1%
|
-22.6%
|
United States
|
|
482
|
 Zura Bio
ZURA
|
$0.12 B | $1.79 |
-23.7%
|
-55.5%
|
United States
|
|
483
|
 XBiotech
XBIT
|
$0.11 B | $3.77 |
-16.2%
|
-16.0%
|
United States
|
|
484
|
 Nanoform Finland Oyj
NANOFH.HE
|
$0.11 B | $1.31 |
-1.1%
|
-39.6%
|
Finland
|
|
485
|
 Editas Medicine
EDIT
|
$0.11 B | $1.34 |
0.83%
|
-85.4%
|
United States
|
|
486
|
 Enanta Pharmaceuticals
ENTA
|
$0.11 B | $5.18 |
-13.9%
|
-56.9%
|
United States
|
|
487
|
 Genelux
GNLX
|
$0.11 B | $3.15 |
2.9%
|
-78.6%
|
United States
|
|
488
|
 Milestone Pharmaceuticals
MIST
|
$0.11 B | $1.99 |
15.7%
|
39.0%
|
Canada
|
|
489
|
 electroCore
ECOR
|
$0.11 B | $16.11 |
-2.2%
|
115.4%
|
United States
|
|
490
|
 Achieve Life Sciences
ACHV
|
$0.11 B | $3.07 |
-24.8%
|
-38.4%
|
Canada
|
|
491
|
 Acumen Pharmaceuticals
ABOS
|
$0.11 B | $1.75 |
-7.8%
|
-50.5%
|
United States
|
|
492
|
 Eurofins-Cerep SA
ALECR.PA
|
$0.10 B | $20403.91 |
0.00%
|
-21.6%
|
France
|
|
493
|
 Nectar Lifesciences
NECLIFE.NS
|
$0.10 B | $0.45 |
-3.2%
|
7.5%
|
India
|
|
494
|
 DBV Technologies
DBVT
|
$0.10 B | $4.74 |
63.5%
|
182.4%
|
France
|
|
495
|
 Tenaya Therapeutics
TNYA
|
$0.10 B | $1.28 |
-15.7%
|
-69.3%
|
United States
|
|
496
|
 IGM Biosciences
IGMS
|
$0.10 B | $1.70 |
-72.3%
|
-85.2%
|
United States
|
|
497
|
 Allakos
ALLK
|
$0.10 B | $1.12 |
-32.3%
|
-27.1%
|
United States
|
|
498
|
 Adocia SA
ADOC.PA
|
$99.67 M | $6.25 |
3.4%
|
-43.2%
|
France
|
|
499
|
 Crossject SA
ALCJ.PA
|
$99.25 M | $2.17 |
-2.8%
|
-60.0%
|
France
|
|
500
|
 DBV Technologies S.A.
DBV.PA
|
$96.51 M | $0.92 |
37.4%
|
-49.4%
|
France
|
|
501
|
 Anixa Biosciences
ANIX
|
$95.79 M | $2.97 |
-6.6%
|
-50.8%
|
United States
|
|
502
|
 ALX Oncology
ALXO
|
$94.94 M | $1.80 |
-4.9%
|
-87.2%
|
United States
|
|
503
|
 HilleVax
HLVX
|
$94.63 M | $1.90 |
1.6%
|
-87.3%
|
United States
|
|
504
|
 Coya Therapeutics
COYA
|
$94.56 M | $5.66 |
-0.65%
|
-8.0%
|
United States
|
|
505
|
 Oramed Pharmaceuticals
ORMP
|
$93.12 M | $2.31 |
-4.2%
|
-0.44%
|
United States
|
|
506
|
 Adverum Biotechnologies
ADVM
|
$92.99 M | $4.47 |
-8.6%
|
-49.9%
|
United States
|
|
507
|
 Pyxis Oncology
PYXS
|
$92.77 M | $1.56 |
-6.3%
|
-52.1%
|
United States
|
|
508
|
 Entera Bio
ENTX
|
$91.71 M | $2.49 |
10.3%
|
172.7%
|
Israel
|
|
509
|
 Jasper Therapeutics
JSPR
|
$90.16 M | $6.01 |
-74.6%
|
-49.6%
|
United States
|
|
510
|
 MediciNova
MNOV
|
$88.77 M | $1.81 |
-11.6%
|
23.6%
|
United States
|
|
511
|
 Immunic
IMUX
|
$88.60 M | $0.98 |
-9.2%
|
-16.4%
|
United States
|
|
512
|
 Leap Therapeutics
LPTX
|
$88.13 M | $2.30 |
-12.4%
|
-10.5%
|
United States
|
|
513
|
 Rani Therapeutics
RANI
|
$87.24 M | $1.49 |
-7.7%
|
-64.3%
|
United States
|
|
514
|
 I-Mab Biopharma
IMAB
|
$87.21 M | $1.07 |
18.9%
|
-38.7%
|
China
|
|
515
|
 Agenus
AGEN
|
$86.42 M | $3.66 |
26.5%
|
-71.0%
|
United States
|
|
516
|
 Karyopharm Therapeutics
KPTI
|
$84.09 M | $0.67 |
10.9%
|
-22.4%
|
United States
|
|
517
|
 Inozyme Pharma
INZY
|
$83.51 M | $1.30 |
-53.6%
|
-70.2%
|
United States
|
|
518
|
 VistaGen Therapeutics
VTGN
|
$83.25 M | $2.99 |
14.5%
|
-41.0%
|
United States
|
|
519
|
 X4 Pharmaceuticals
XFOR
|
$83.21 M | $0.49 |
-12.4%
|
-32.2%
|
United States
|
|
520
|
 Vigil Neuroscience
VIGL
|
$82.99 M | $2.03 |
18.4%
|
-36.7%
|
United States
|
|
521
|
 Tiziana Life Sciences
TLSA
|
$82.74 M | $0.80 |
7.2%
|
25.4%
|
United Kingdom
|
|
522
|
 Inovio Pharmaceuticals
INO
|
$81.23 M | $2.25 |
13.7%
|
-70.1%
|
United States
|
|
523
|
 Regulus Therapeutics
RGLS
|
$81.22 M | $1.24 |
-19.5%
|
1.6%
|
United States
|
|
524
|
 Scilex Holding
SCLX
|
$80.63 M | $0.44 |
6.9%
|
-72.5%
|
United States
|
|
525
|
 Sellas Life Sciences
SLS
|
$80.24 M | $1.14 |
14.0%
|
103.8%
|
United States
|
|
526
|
 Adagene
ADAG
|
$79.69 M | $1.80 |
-5.2%
|
-43.3%
|
China
|
|
527
|
 Theratechnologies
THTX
|
$79.42 M | $1.72 |
-3.3%
|
2.9%
|
Canada
|
|
528
|
 Armata Pharmaceuticals
ARMP
|
$79.24 M | $2.19 |
0.98%
|
-47.2%
|
United States
|
|
529
|
 InterCure
INCR
|
$78.72 M | $1.72 |
1.5%
|
38.0%
|
Israel
|
|
530
|
 Skye Bioscience
SKYE
|
$78.58 M | $2.59 |
4.3%
|
15.7%
|
United States
|
|
531
|
 Nykode Therapeutics
NYKD.OL
|
$78.40 M | $0.24 |
-8.3%
|
-85.5%
|
Norway
|
|
532
|
 Assertio Therapeutics
ASRT
|
$77.34 M | $0.81 |
-5.7%
|
-2.4%
|
United States
|
|
533
|
 Journey Medical
DERM
|
$76.87 M | $3.68 |
-18.5%
|
-33.1%
|
United States
|
|
534
|
 Adlai Nortye
ANL
|
$76.84 M | $2.08 |
-12.7%
|
-78.0%
|
|
|
535
|
 Cue Biopharma
CUE
|
$76.65 M | $1.21 |
29.7%
|
-53.9%
|
United States
|
|
536
|
 bluebird bio
BLUE
|
$76.22 M | $7.84 |
7.2%
|
-64.3%
|
United States
|
|
537
|
 Galectin Therapeutics
GALT
|
$75.94 M | $1.21 |
47.6%
|
-27.9%
|
United States
|
|
538
|
 ESSA Pharma
EPIX
|
$75.90 M | $1.71 |
8.1%
|
-79.6%
|
Canada
|
|
539
|
 Adicet Bio
ACET
|
$75.64 M | $0.92 |
-0.87%
|
-63.8%
|
United States
|
|
540
|
 Aadi Bioscience
AADI
|
$73.80 M | $2.99 |
-0.67%
|
71.3%
|
United States
|
|
541
|
 Annovis Bio
ANVS
|
$73.26 M | $5.31 |
0.00%
|
-57.0%
|
United States
|
|
542
|
 Aerovate Therapeutics
AVTE
|
$73.14 M | $2.53 |
-0.77%
|
-87.3%
|
United States
|
|
543
|
 Applied Therapeutics
APLT
|
$73.12 M | $0.63 |
-23.4%
|
-75.8%
|
United States
|
|
544
|
 Genenta Science
GNTA
|
$72.98 M | $3.99 |
-23.4%
|
-9.3%
|
Italy
|
|
545
|
 Clearside Biomedical
CLSD
|
$72.42 M | $0.95 |
0.11%
|
-22.5%
|
United States
|
|
546
|
 Vivani Medical
VANI
|
$72.27 M | $1.22 |
3.4%
|
17.6%
|
United States
|
|
547
|
 Ikena Oncology
IKNA
|
$70.94 M | $1.47 |
-2.0%
|
7.1%
|
United States
|
|
548
|
 BeyondSpring
BYSI
|
$70.53 M | $1.75 |
1.8%
|
91.5%
|
United States
|
|
549
|
 Rockwell Medical
RMTI
|
$70.45 M | $2.18 |
-1.4%
|
46.2%
|
United States
|
|
550
|
 Context Therapeutics
CNTX
|
$70.33 M | $0.94 |
-12.2%
|
-0.98%
|
United States
|
|
551
|
 Quince Therapeutics
QNCX
|
$68.64 M | $1.56 |
-2.9%
|
30.7%
|
United States
|
|
552
|
 PMV Pharmaceuticals
PMVP
|
$68.31 M | $1.32 |
-6.8%
|
-19.4%
|
United States
|
|
553
|
 Oncolytics Biotech
ONCY
|
$67.83 M | $0.88 |
-13.4%
|
-31.7%
|
Canada
|
|
554
|
 Mural Oncology
MURA
|
$67.39 M | $3.95 |
27.8%
|
-6.3%
|
Ireland
|
|
555
|
 OptiNose
OPTN
|
$67.27 M | $6.69 |
11.6%
|
-70.0%
|
United States
|
|
556
|
 CytomX Therapeutics
CTMX
|
$65.57 M | $0.84 |
-21.5%
|
-47.8%
|
United States
|
|
557
|
 Immuneering
IMRX
|
$65.52 M | $2.11 |
-10.2%
|
-65.5%
|
United States
|
|
558
|
 Mersana Therapeutics
MRSN
|
$65.16 M | $0.53 |
-61.8%
|
-80.0%
|
United States
|
|
559
|
 Verrica Pharmaceuticals
VRCA
|
$64.87 M | $0.72 |
-1.3%
|
-88.3%
|
United States
|
|
560
|
 Regencell Bioscience
RGC
|
$64.54 M | $4.96 |
-3.3%
|
-44.5%
|
Hong Kong
|
|
561
|
 PepGen
PEPG
|
$64.54 M | $1.98 |
-42.9%
|
-66.6%
|
United States
|
|
562
|
 Prelude Therapeutics
PRLD
|
$64.39 M | $1.17 |
-11.8%
|
-67.1%
|
United States
|
|
563
|
 Generation Bio
GBIO
|
$63.83 M | $0.96 |
-11.4%
|
-49.0%
|
United States
|
|
564
|
 iCAD
ICAD
|
$63.51 M | $2.41 |
10.7%
|
27.9%
|
United States
|
|
565
|
 PDS Biotechnology
PDSB
|
$62.85 M | $1.68 |
-11.6%
|
-71.2%
|
United States
|
|
566
|
 Cytosorbents
CTSO
|
$62.15 M | $1.02 |
15.3%
|
12.4%
|
United States
|
|
567
|
 Reneo Pharmaceuticals
RPHM
|
$60.84 M | $18.20 |
0.00%
|
8.3%
|
United States
|
|
568
|
 Werewolf Therapeutics
HOWL
|
$60.61 M | $1.36 |
-13.6%
|
-66.1%
|
United States
|
|
569
|
 Kronos Bio
KRON
|
$60.34 M | $1.00 |
4.3%
|
-18.1%
|
United States
|
|
570
|
 Tonix Pharmaceuticals
TNXP
|
$59.62 M | $0.32 |
-38.5%
|
-97.4%
|
United States
|
|
571
|
 IO Biotech
IOBT
|
$59.30 M | $0.90 |
-4.2%
|
-51.8%
|
Denmark
|
|
572
|
 Boundless Bio
BOLD
|
$57.31 M | $2.57 |
-1.9%
|
-82.2%
|
United States
|
|
573
|
 Groupe Berkem SA
ALKEM.PA
|
$56.81 M | $3.23 |
0.00%
|
-3.1%
|
France
|
|
574
|
 Immix Biopharma
IMMX
|
$54.47 M | $1.98 |
-6.4%
|
-56.6%
|
United States
|
|
575
|
 Shattuck Labs
STTK
|
$53.47 M | $1.12 |
0.00%
|
-88.3%
|
United States
|
|
576
|
 Celularity
CELU
|
$52.16 M | $2.32 |
0.88%
|
-18.1%
|
United States
|
|
577
|
 Outlook Therapeutics
OTLK
|
$52.05 M | $2.09 |
51.7%
|
-74.9%
|
United States
|
|
578
|
 Elton International Trading Company S.A.
ELTON.AT
|
$51.76 M | $1.94 |
0.76%
|
-7.2%
|
Greece
|
|
579
|
 Repare Therapeutics
RPTX
|
$51.44 M | $1.21 |
-8.1%
|
-80.3%
|
Canada
|
|
580
|
 Rafael Holdings
RFL
|
$51.22 M | $2.07 |
11.7%
|
20.4%
|
United States
|
|
581
|
 FibroGen
FGEN
|
$50.79 M | $0.50 |
14.8%
|
-35.8%
|
United States
|
|
582
|
 MAIA Biotechnology
MAIA
|
$50.22 M | $1.92 |
0.50%
|
37.0%
|
United States
|
|
583
|
 Fortress Biotech
FBIO
|
$49.96 M | $1.81 |
3.3%
|
-6.5%
|
United States
|
|
584
|
 Ovid Therapeutics
OVID
|
$49.92 M | $0.70 |
-23.4%
|
-78.2%
|
United States
|
|
585
|
 LakeShore Biopharma
LSB
|
$48.66 M | $2.55 |
-14.9%
|
-44.1%
|
China
|
|
586
|
 Invivyd
IVVD
|
$48.64 M | $0.41 |
-20.4%
|
-90.9%
|
United States
|
|
587
|
 Lantern Pharma
LTRN
|
$48.32 M | $4.48 |
18.1%
|
-10.7%
|
United States
|
|
588
|
 Spero Therapeutics
SPRO
|
$47.65 M | $0.87 |
-3.0%
|
-39.5%
|
United States
|
|
589
|
 Kezar Life Sciences
KZR
|
$46.70 M | $6.40 |
-5.6%
|
-24.5%
|
United States
|
|
590
|
 AlloVir
ALVR
|
$46.37 M | $9.20 |
-14.9%
|
-39.8%
|
United States
|
|
591
|
 Clicks Group
CLS.JO
|
$45.77 M | $19.23 |
-4.4%
|
21.0%
|
South Africa
|
|
592
|
 Aileron Therapeutics
ALRN
|
$45.72 M | $1.94 |
-7.8%
|
-57.4%
|
United States
|
|
593
|
 Serina Therapeutics
SER
|
$44.71 M | $4.76 |
-8.0%
|
-65.9%
|
United States
|
|
594
|
 RAPT Therapeutics
RAPT
|
$42.65 M | $1.22 |
-30.6%
|
-95.2%
|
United States
|
|
595
|
 Barinthus Biotherapeutics
BRNS
|
$42.24 M | $1.05 |
2.7%
|
-62.4%
|
United Kingdom
|
|
596
|
 NRx Pharmaceuticals
NRXP
|
$42.09 M | $3.48 |
155.4%
|
-4.5%
|
United States
|
|
597
|
 Q32 Bio
QTTB
|
$41.90 M | $3.44 |
-0.91%
|
-69.1%
|
United States
|
|
598
|
 Iterum Therapeutics
ITRM
|
$41.82 M | $1.52 |
-12.6%
|
-23.6%
|
Ireland
|
|
599
|
 Actinium Pharmaceuticals
ATNM
|
$41.18 M | $1.32 |
14.8%
|
-72.8%
|
United States
|
|
600
|
 Aspen Pharmacare
APN.JO
|
$41.18 M | $9.27 |
0.75%
|
-6.9%
|
South Africa
|